You are here

Xiaofei Yin

Publications

Zhang KJ, Yin XF, Yang YQ, et al.. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clin Cancer Res. 2017;23(8):2038-2049. doi:10.1158/1078-0432.CCR-16-1386

Yang YQ, Dong WJ, Yin XF, et al. Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells. Protein Cell. 2016;7(7):538-543. doi:10.1007/s13238-016-0281-6

Xiaofei Yin, Ph.D.

Xiaofei Yin is a research scientist I in the Cardiovascular Disease Initiative (CVDi) at the Broad Institute of MIT and Harvard. She works as part of the Broad-Bayer collaboration to support an early drug development program. Yin's research investigates the molecular and cellular mechanisms of a potential therapeutic target for liver disease.

Prior to joining the Broad Institute in January 2022, Yin completed postdoctoral research training in Daniel Kelly’s lab at the Cardiovascular Institute at the University of Pennsylvania, where she studied the functions and mechanisms of MondoA in obesity and metabolic syndrome, as well as the role of Sdha in heart failure. 

Yin obtained her Ph.D. in biochemistry and molecular Biology from University of Chinese Academy of Sciences, Shanghai, China, carrying out her thesis research on the anti-cancer mechanism of a novel recombinant interferon derived from human IFNα-2b by mutagenesis. She also holds a bachelor’s degree in biology from Shandong University, Shandong, China.

November 2022